Analysis of pre-chemotherapy WBC, PLT, monocyte, hemoglobin, and MPV levels in acute myeloid leukemia patients with WT1, FLT3, or NPM gene mutations

• Published in: Medicine (Baltimore) 2020-04, Vol.99 (14), p.e19627-e19627
• Main Authors: Merdin, Alparslan, Dal, Mehmet Sinan, Çakar, Merih Kizil, Yildiz, Jale, Ulu, Bahar Uncu, Batgi, Hikmetullah, Tetik, Ayşegül, Seçilmiş, Sema, Darçin, Tahir, Şahin, Derya, Bakirtaş, Mehmet, Başçi, Semih, Yiğenoğlu, Tuğçe Nur, Baysal, Nuran Ahu, İskender, Dicle, Altuntaş, Fevzi
• Format: Article
• Language: English
• Subjects: Adult; Female; fms-Like Tyrosine Kinase 3 - blood; fms-Like Tyrosine Kinase 3 - genetics; Hemoglobins - analysis; Humans; Leukemia, Myeloid, Acute - blood; Leukemia, Myeloid, Acute - drug therapy; Leukemia, Myeloid, Acute - genetics; Leukocytes; Male; Mean Platelet Volume; Monocytes - metabolism; Mutation; Nuclear Proteins - blood; Nuclear Proteins - genetics; Observational Study; Platelet Count; WT1 Proteins - blood; WT1 Proteins - genetics
• ISSN: 0025-7974; 1536-5964
• DOI: 10.1097/MD.0000000000019627

Effects of mutations on AML (acute myeloid leukemia) patients have been an area of clinical interest. The aim of this study was to analyze pre-chemotherapy WBC (white blood cell), platelet, monocyte, hemoglobin, and mean platelet volume (MPV) levels in acute myeloid leukemia patients with Wilms tumor 1 (WT1), FMS-like tyrosine kinase 3 (FLT3), or nucleophosmin (NPM) gene mutations, attempting to detect and compare possible differences in these values.The study included 71 patients with acute myeloid leukemia known to have WT1, FLT3, or NPM gene mutations. The patients were divided into 3 groups: FLT3-mutated AML patients without any accompanying known mutations other than WT1 at the time of diagnosis (Group 1), NPM-mutated AML patients without any accompanying known mutations other than WT1 at the time of diagnosis (Group 2), WT1-mutated AML patients with no other accompanying known mutations at the time of diagnosis (Group 3). We carried out intergroup comparisons of WBC, platelet (PLT), monocyte, hemoglobin, and MPV levels before chemotherapy.There was a statistically significant difference between the groups in terms of WBC parameters (P = .001). There were no statistically significant differences between the groups with respect to hemoglobin, platelet, and monocyte levels.Higher white blood cell counts could be observed in patients with FLT3-mutated AML.